Array BioPharma Inc. (NASDAQ:ARRY) marched up 146.51% compared to a 52-week low price of $6.73. The shares were last seen trading -5.52% lower, taking the closing price at $16.59 on 02/13/2018. At recent session, the prices were hovering between $16.43 and $17.45. This company shares are 16.52% off its target price of $19.33 and the current market capitalization stands at $3.24B. The recent change has given its price a 25.28% lead over SMA 50 and -9.05% deficit over its 52-week high. The stock witnessed 21.01% gains, 50.82% gains and 84.13% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ARRY’s volatility during a week at 7.98% and during a month it has been found around 7.06%.Array BioPharma Inc. (ARRY) Top Holders
Institutional investors currently hold around $3.43 billion or 0% in ARRY stock. Look at its top three institutional owners. Fmr Llc owns $389.52 million in Array BioPharma Inc., which represents roughly 12.02% of the company’s market cap and approximately 11.37% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 19,783,311 shares of the stock are valued at $347.4 million. The third largest holder is Redmile Group, Llc, which currently holds $308.29 million worth of this stock and that ownership represents nearly 9.52% of its market capitalization.
At the end of 12/31/2017 reporting period, 108 institutional holders increased their position in Array BioPharma Inc. (NASDAQ:ARRY) by some 36,205,916 shares, 88 decreased positions by 17,085,715 and 26 held positions by 141,817,649. That puts total institutional holdings at 195,109,280 shares, according to SEC filings. The stock grabbed 41 new institutional investments totaling 10,402,276 shares while 38 institutional investors sold out their entire positions totaling 5,515,473 shares.Array BioPharma Inc. (NASDAQ:ARRY) Insider Trades
Multiple company employees have indulged in significant insider trading. Array BioPharma Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Baum Charles M has sold 50,000 shares of Array BioPharma Inc. (ARRY) in trading session dated Feb. 09, 2018. These shares are worth $845,000 and were traded at $16.9 each. The SEC filing shows that Lefkoff Kyle performed a sale of 50,000 shares. The Director disposed these shares by way of transaction on Feb. 09, 2018. The company’s shares were given away at $17.01 per share worth to an income of some $850,500 on account of Lefkoff Kyle.
Director, Van Lunsen Gil J, sold 21,500 common shares of Array BioPharma Inc. (ARRY) in the open market. In a transaction dated Jan. 17, 2018, the shares were put up for sale at an average price of $12.94, raking in a sum of $278,210. After this sale, 19,297 common shares of ARRY are directly owned by the insider, with total stake valued at $320,137.
In the transaction dated Jan. 16, 2018, the great number of shares disposed came courtesy the CFO; Haddock Jason disposed a total of 7,500 shares at an average price of $13.73, amounting to approximately $102,975. The insider now directly owns 28,868 shares worth $478,920.Array BioPharma Inc. (ARRY) Analyst Guide
Several analysts have released their opinion on Array BioPharma Inc. (NASDAQ:ARRY), with 9 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.